title: [New oral anticoagulant pharmacology].
abstract: All new oral anticoagulants are direct specific reversible inhibitors, either direct factor Xa inhibitors or inhibitors of thrombin. The pharmacokinetic of the new drugs is mediated by P- glycoprotein (P-gp) and metabolised by liver enzymes for some of them, principally cytochrome P450. That explains an important risk of drug interactions. The particularity of these new drugs is a priori a pharmacokinetic and pharmacodynamic profile more predictable involving no need for laboratory monitoring. In some clinical situations (risk of too high or too low exposure), a specific dose is proposed.
authors.affiliation: CHU de Saint-Étienne, hôpital Nord, laboratoire de pharmacologie-toxicologie, 42055 Saint-Étienne, France; Université Jean-Monnet, groupe de recherche sur la thrombose, EA3065, Saint-Étienne, France. Electronic address: xavier.delavenne@chu-st-etienne.fr.
authors.forename: Xavier
authors.initials: X
authors.lastname: Delavenne
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000502:physiology; D004347:Drug Interactions; D006801:Humans; D012307:Risk Factors
chemical_list: D000925:Anticoagulants